No more baby steps
Nothing was ordinary about the first civil trial stemming from Pfizer's controversial epilepsy treatment, Neurontin. Both sides loudly complained about witness intimidation. Colourful plaintiffs lawyer Mark Lanier opened to the jury one day, then settled the next after an anonymous donor deposited $50,000 (£31,000) into an account for the alleged victim's daughter. And at the defence table, high-powered product liability specialists from three separate firms worked as though they were partners - and all on a flat fee basis. "It was," says Pfizer general counsel Amy Schulman, "an extraordinary victory."
After a terrific run as a partner at DLA Piper, Pfizer’s Amy Schulman knows how the game is played and has set out to change all the rules. Amy Miller reports
This premium content is reserved for
Legal Week Subscribers.
Subscribe today and get 10% off.
A PREMIUM SUBSCRIPTION PROVIDES:
- Trusted insight, news and analysis from the UK and across the globe
- Connections to senior business lawyers within the leading law firms and legal departments
- Optimized access on all of your devices: desktop, tablet and mobile
- Complete access to the site's full archive of more than 56,000 articles
Already have an account? Sign In Now